Pacific Biosciences of California Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 112/207 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.25.In the medium term, the stock price is expected to trend up.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Pacific Biosciences of California Inc's Score
Industry at a Glance
Industry Ranking
112 / 207
Overall Ranking
279 / 4563
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
10
analysts
Buy
Current Rating
2.250
Target Price
-3.02%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Pacific Biosciences of California Inc Highlights
StrengthsRisks
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 20.04% year-on-year.
Overvalued
The company’s latest PE is -1.06, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 166.98M shares, decreasing 36.91% quarter-over-quarter.
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Ticker SymbolPACB
CompanyPacific Biosciences of California Inc
CEOHenry (Christian O)
Websitehttps://www.pacb.com/
FAQs
What is the current price of Pacific Biosciences of California Inc (PACB)?
The current price of Pacific Biosciences of California Inc (PACB) is 1.770.
What is the symbol of Pacific Biosciences of California Inc?
The ticker symbol of Pacific Biosciences of California Inc is PACB.
What is the 52-week high of Pacific Biosciences of California Inc?
The 52-week high of Pacific Biosciences of California Inc is 2.725.
What is the 52-week low of Pacific Biosciences of California Inc?
The 52-week low of Pacific Biosciences of California Inc is 0.851.
What is the market capitalization of Pacific Biosciences of California Inc?
The market capitalization of Pacific Biosciences of California Inc is 534.28M.
What is the net income of Pacific Biosciences of California Inc?
The net income of Pacific Biosciences of California Inc is -309.85M.
Is Pacific Biosciences of California Inc (PACB) currently rated as Buy, Hold, or Sell?
According to analysts, Pacific Biosciences of California Inc (PACB) has an overall rating of Buy, with a price target of 2.250.
What is the Earnings Per Share (EPS TTM) of Pacific Biosciences of California Inc (PACB)?
The Earnings Per Share (EPS TTM) of Pacific Biosciences of California Inc (PACB) is -1.670.